Celgene taps Cypher Genomics for cancer R&D; Aura snags orphan tag;

@FierceBiotech: Regeneron's arthritis drug aces Phase III with the FDA in sight. News | Follow @FierceBiotech

@JohnCFierce: What's your list of top 5 public biotechs? (Potential, management, smart execution) I'd put $BLUE in that group. Any other suggestions? | Follow @JohnCFierce

> Celgene ($CELG) has reached out to Cypher Genomics to collaborate on determining the ideal patients for clinical trials in oncology. News

> Aura Biosciences picked up the FDA's orphan drug designation for its in-development treatment for uveal melanoma. More

Medical Device News

@FierceMedDev: ICYMI yesterday: MD Anderson Cancer Center partners to start breast cancer pilot project using Apple Watch. Report | Follow @FierceMedDev

@VarunSaxena2: St. Jude says alternative imaging system is optimal during stenting procedures. Story | Follow @VarunSaxena2

@EmilyWFierce: San Francisco startup reels in $30M for disease outbreak prediction tech. More  | Follow @EmilyWFierce

> Philips collaborates with Dutch hospital to develop diabetic foot disease Dx. More

> Issue that led to halt of St. Jude TAVR trial no cause for concern, EuroPCR experts say. News

Pharma News

@FiercePharma:  NIH steps in with $9M Vanderbilt grant after rough season for flu vaccines. More | Follow @FiercePharma

@EricPFierce: ICYMI: #FDA blesses Baxter #saline plant in Spain for shipments to U.S. of  0.9% sodium chloride. Article | Follow @EricPFierce

@CarlyHFierce: Novo, Baxter spar over hemophilia patent amid ITC probe. Story | Follow @CarlyHFierce

> Report: Cadila next in line for injectables bulk-up as it nears deal for Claris. More

> Aspen unloads $301M worth of meds to fuel expansion abroad. News

Vaccines News

> Canadian biotech Medicago building $200M vaccine plant. Item

> Genocea's genital herpes vaccine succeeds in Ph II. More

> Takeda, Daiichi Sankyo ink flu vaccine distribution pacts with Japan's Kaketsuken. Story

> Zydus Cadila preps for big splash into India's vaccines market. Article

> U.K.'s PsiOxus scores $39M for colorectal cancer vaccine combo trial. Report

CRO News

> Quintiles' founders bank $770M in secondary offering. Item

> InVentiv invests in compliance as regulations shift for real-world studies. Story

> Quotient Clinical soars in its first year after a PE buyout. Report

> WuXi posts another big quarter as it faces a big decision. Article

Pharma Manufacturing News

> Hospira recalls solution marked as heparin. Item

> Zydus Cadila said to be buying Claris' sterile injectables biz as landscape morphs. Story

> Apotex recalling generic Zyprexa because the antipsychotic may be too weak. News

> Fund grows to $200M for victims of meningitis outbreak tied to compounder. Article

> Medicago building $200M plant to manufacture vaccines from plants. Report

Pharma Asia News

> Sinocare said to bid $1B for Bayer diabetes devices, piping Panasonic. More

> China academy plans clinical trials on artemisinin derivative aimed at lupus. News

> Japan eyes higher target for generics despite missing earlier aims. Article

> Gilead's Sovaldi faces renewed advocacy CL pressure, this time for China and Russia. Story

> Glenmark gets India nod on shares sales to foreign investors, Temasek in. Report

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.